Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. (SNSE): 7 pipeline candidates · ~56 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
56.1 months
D/E -0.10 · 0% dilution
Lead: Phase 1/Phase 2
7 candidates
N/A
26 buys · 29 sells (180d)
A transparent, data-derived signal for Sensei Biotherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$18.6M
Cash
$152.3M
Quarterly Burn
$10.7M
Runway
56.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| cemiplimab | Phase 1/Phase 2 |
| piktor | Phase 2 |
| sns-101 | Phase 1/Phase 2 |
| sns-102 | Preclinical |
| sns-103 | Preclinical |
| sns-201 | Preclinical |
| solnerstotug | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$45.6M
| Holder | Shares | Value |
|---|---|---|
| woodline partners lp | 361,010 | $11.4M |
| stempoint capital lp | 265,746 | $8.4M |
| millennium management llc | 146,565 | $4.6M |
| franklin resources inc | 133,506 | $4.2M |
| caligan partners lp | 126,002 | $4.0M |
| marshall wace, llp | 65,730 | $2.1M |
| goldman sachs group inc | 61,568 | $1.9M |
| suvretta capital management, llc | 34,549 | $1.1M |
| bank of america corp /de/ | 33,025 | $1.0M |
| renaissance technologies llc | 32,041 | $1.0M |
Showing top 10 of 28 institutional holders of Sensei Biotherapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sensei Biotherapeutics, Inc.'s pipeline?
Sensei Biotherapeutics, Inc. (SNSE) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sensei Biotherapeutics, Inc.'s lead drug candidate?
Sensei Biotherapeutics, Inc.'s most advanced tracked candidate is cemiplimab (Phase 1/Phase 2) for Solid Tumor, Adult.
What is Sensei Biotherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sensei Biotherapeutics, Inc. has approximately 56.1 months of cash runway.
What is Sensei Biotherapeutics, Inc.'s market capitalization?
Sensei Biotherapeutics, Inc.'s market capitalization is approximately $18.6M.
Who is the CEO of Sensei Biotherapeutics, Inc.?
John Celebi is the chief executive officer of Sensei Biotherapeutics, Inc. (SNSE).
Get the full picture on Sensei Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.